PDUFA VII Negotiations Completed, Commitment Letter Ratification Ongoing
The US FDA, HHS and White House, as well as industry groups, now must sign off on the document.
You may also be interested in...
New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.
CBER Reorganization Aims To Fight Recruitment Challenges, Tackle Upcoming Gene Therapy Wave
A growing focus on real-world evidence and an expected infusion of user fee funding are among the reasons for the new office branches at US FDA’s biologics center.
FDA Creates Division To Support First Amendment Policy Development, Oversee Advertising Research
Multiple unfavorable court decisions have forced the agency to adjust its advertising enforcement strategies.